Preparation of Ferritin Nanoparticles Displaying the Dominant Neutralizing Epitopes of Foot-and-mouth disease virus and Their Immunogenicity Evaluation in Mouse (Mus musculus) Models
LU Bing-Zhou1,2, RU Yi2, HAO Rong-Zeng2, LI Ya-Jun2, YANG Yang2, YANG Rui1, MAO Yu-Han2, JIANG Cheng-Hui2, TAO Shi-Yu1, ZHENG Hai-Xue2, YU Si-Jiu1, CUI Yan1,*
1 College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China; 2 Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences/State Key Laboratory of Veterinary Etiological Biology, Lanzhou 730046, China
Abstract Nanoparticles (NPs) can display multiple copies of antigen on the surface and simulate the structural morphology of viruses, which is more conducive to uptake by immune cells and promote antigen presentation, thus enhancing protective efficacy. This study aimed to generate ferritin nanoparticles harboring a dominant neutralizing epitope of Foot-and-mouth disease virus (FMDV) by using the Escherichia coli expression system, and to evaluate its immunogenicity. The recombinant expression plasmid pET28a-FBT was constructed based on the Helicobacter pylori ferritin, the dominant neutralizing epitope sequence of FMDV was inserted between the 33th and 34th amino acids of ferritin, and the T cell epitope sequence was inserted at the N-terminus of ferritin. The recombinant expression plasmid pET28a-Fer expressing Fer protein was used as control. The recombinant plasmid pET28a-Fer and pET28a-FBT were transformed into Escherichia coli competent cells, the target proteins were obtained by induced expression and size exclusion chromatography purification, and identified using SDS-PAGE, Western blot, particle size analysis, and transmission electron microscopy, then evaluated immunogenicity by immunizing BALB/c mice (Mus muculus). The results showed that the recombinant protein Fer and FBT were successfully prepared by using prokaryotic expression system. The recombinant protein FBT could be recognized specifically by FMDV positive serum. After 14 d of immunization with FBT, serum antibodies were produced and continued to rise, and the neutralizing antibody titer could reach up to 1∶128 on 35 d. At the same time, the proliferation level of spleen lymphocytes and the secretion level of interleukin 2 (IL-2), IL-4, IL-10, and interferon-γ (IFN-γ) in FBT immunized mice were significantly higher than the control (P<0.05). This study prepared ferritin nanoparticles displaying FMDV neutralizing epitopes with good immunogenicity, providing technical support for the development of a novel foot-and-mouth disease engineered vaccine.
LU Bing-Zhou,RU Yi,HAO Rong-Zeng, et al. Preparation of Ferritin Nanoparticles Displaying the Dominant Neutralizing Epitopes of Foot-and-mouth disease virus and Their Immunogenicity Evaluation in Mouse (Mus musculus) Models[J]. 农业生物技术学报, 2024, 32(5): 1216-1226.
[1] 曹轶梅, 王兴凯, 王省, 等. 2019. 三种大肠杆菌表达的口蹄疫病毒A型多表位蛋白对猪的免疫原性比较[J]. 微生物学报, 59(4): 711-718. (Cao Y M, Wang X K, Wang S, et al.2019. Comparison of immunogenicity of Foot-and-mouth disease virus type A multiepitope expressed by three E. coli strains to pigs[J]. Chinese Journal of Microbiology, 59(4): 711-718.) [2] 何继军, 马维民, 吕律, 等. 2022. 近五年我国口蹄疫流行毒株鉴定与溯源[J]. 中国兽医科学, 52: 6-9. (He J J, Ma W M, Lv L, et al.2022. The identification and tracking of epidemic strains of Foot-and-mouth disease virus in China over the past five years[J]. Chinese Veterinary Sience, 52: 6-9.) [3] Brown F, Benkirane N, Limal D, et al.1999. Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of Foot-and-mouth disease virus VP1 which does not contain the RGD motif[J]. Vaccine, 18(1-2): 50-56. [4] Burman A, Clark S, Abrescia N G, et al.2006. Specificity of the VP1 GH loop of Foot-and-mouth disease virus for alphav integrins[J]. Journal of Virology, 80(19): 9798-9810. [5] Cai Y, Wang Y, Xu H, et al.2019. Positive magnetic resonance angiography using ultrafine ferritin-based iron oxide nanoparticles[J]. Nanoscale, 11(6): 2644-2654. [6] Cañas-Arranz R, de León P, Forner M, et al.2020a. Immunogenicity of a dendrimer B(2)T peptide harboring a T-cell epitope from FMDV non-structural protein 3D[J]. Frontier in Veterinary Science, 7: 498. [7] Cañas-Arranz R, Forner M, Defaus S, et al.2020b. A single dose of dendrimer B(2)T peptide vaccine partially protects pigs against Foot-and-mouth disease virus infection[J]. Vaccines (Basel), 8(1): 19. [8] Capozzo A V, Vosloo W, de Los S T, et al.2023. Foot-and-mouth disease epidemiology, vaccines and vaccination: Moving forward[J]. Frontier in Veterinary Science, 10: 1231005. [9] Clarke B E, Newton S E, Carroll A R, et al.1987. Improved immunogenicity of a peptide epitope after fusion to Hepatitis B core protein[J]. Nature, 330(6146): 381-384. [10] Cohen A A, Gnanapragasam P, Lee Y E, et al.2021. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice[J]. Science, 371(6530): 735-741. [11] Condy J B, Hedger R S, Hamblin C, et al.1985. The duration of the Foot-and-mouth disease virus carrier state in African buffalo (i) in the individual animal and (ii) in a free-living herd[J]. Comparative Immunology Microbiology & Infectious Diseases, 8(3-4): 259-265. [12] Cox J.2001. Foot and mouth disease[J]. British Journal of General Practice, 51(466): 417. [13] Diaz-San S F, Medina G N, Stenfeldt C, et al.2017. Foot-and-mouth disease vaccines[J]. Veterinary Microbiology, 206: 102-112. [14] Dimarchi R, Brooke G, Gale C, et al.1986. Protection of cattle against foot-and-mouth disease by a synthetic peptide[J]. Science, 232(4750): 639-641. [15] Englezou P C, Sapet C, Démoulins T, et al.2018. Self-amplifying replicon RNA delivery to dendritic cells by cationic lipids[J]. Molecular Therapy Nucleic Acids, 12: 118-134. [16] Grubman M J, Baxt B.2004. Foot-and-mouth disease[J]. Clinical Microbiology Reviews, 17(2): 465-493. [17] He L, de Val N, Morris C D, et al.2016. Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles[J]. Nature Communications, 7: 12041. [18] He L, Tzarum N, Lin X, et al.2020. Proof of concept for rational design of Hepatitis C virus E2 core nanoparticle vaccines[J]. Science Advances, 6(16): eaaz6225. [19] Kalathiya U, Padariya M, Fahraeus R, et al.2021. Multivalent display of SARS-CoV-2 spike (RBD Domain) of COVID-19 to nanomaterial, protein ferritin nanocages[J]. Biomolecules, 11(2): 297. [20] Kanekiyo M, Bu W, Joyce M G, et al.2015. Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site[J]. Cell, 162(5): 1090-1100. [21] Kanekiyo M, Wei C J, Yassine H M, et al.2013. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies[J]. Nature, 499(7456): 102-106. [22] Karch C P, Burkhard P.2016. Vaccine technologies: From whole organisms to rationally designed protein assemblies[J]. Biochemical Pharmacology, 120: 1-14. [23] Kelly H G, Kent S J, Wheatley A K.2019. Immunological basis for enhanced immunity of nanoparticle vaccines[J]. Expert Review of Vaccines, 18(3): 269-280. [24] Kim Y I, Kim D, Yu K M, et al.2021. Development of spike receptor-binding domain nanoparticles as a vaccine candidate against SARS-CoV-2 infection in ferrets[J]. mBio, 12(2): e00230. [25] Knight-Jones T J, Rushton J.2013. The economic impacts of foot and mouth disease - what are they, how big are they and where do they occur?[J]. Preventive Veterinary Medicine, 112(3-4): 161-173. [26] Lewis J D, Destito G, Zijlstra A, et al.2006. Viral nanoparticles as tools for intravital vascular imaging[J]. Nature Medicine, 12(3): 354-360. [27] Li P, Lu Z, Bai X, et al.2014. Evaluation of a 3A-truncated Foot-and-mouth disease virus in pigs for its potential as a marker vaccine[J]. Veterinary Research, 45(1): 51. [28] Li Y, Jin Q, Ding P, et al.2020. Gold nanoparticles enhance immune responses in mice against recombinant Classical swine fever virus E2 protein[J]. Biotechnology Letters, 42(7): 1169-1180. [29] López-Sagaseta J, Malito E, Rappuoli R, et al.2016. Self-assembling protein nanoparticles in the design of vaccines[J]. Computation Structural Biotechnology Journal, 14: 58-68. [30] Lu Z, Yu S, Wang W, et al.2022. Development of foot-and-mouth disease vaccines in recent years[J]. Vaccines (Basel), 10(11): 1817. [31] Murji A A, Qin J S, Hermanus T, et al.2021. Elicitation of neutralizing antibody responses to HIV-1 immunization with nanoparticle vaccine platforms[J]. Viruses, 13(7): 1296. [32] Negahdaripour M, Golkar N, Hajighahramani N, et al.2017. Harnessing self-assembled peptide nanoparticles in epitope vaccine design[J]. Biotechnology Advances, 35(5): 575-596. [33] Ochoa W F, Kalko S G, Mateu M G, et al.2000. A multiply substituted G-H loop from Foot-and-mouth disease virus in complex with a neutralizing antibody: A role for water molecules[J]. Journal of General Virology, 81(6): 1495-1505. [34] Pattnaik A, Sahoo B R, Struble L R, et al.2023. A ferritin nanoparticle-based Zika virus vaccine candidate induces robust humoral and cellular immune responses and protects mice from lethal virus challenge[J]. Vaccines (Basel), 11(4): 821. [35] Rangel G, Bárcena J, Moreno N, et al.2021. Chimeric RHDV virus-like particles displaying Foot-and-mouth disease virus epitopes elicit neutralizing antibodies and confer partial protection in pigs[J]. Vaccines (Basel), 9(5): 470. [36] Reed L J, Muench H.1938. A simple method of estimating fifty percent endpoints[J]. American Journal of Epidemiology, 27(3): 493-497. [37] Summerfield A, Guzylack-Piriou L, Harwood L, et al.2009. Innate immune responses against Foot-and-mouth disease virus: Current understanding and future directions[J]. Veterinary Immunology and Immunopathology, 128(1-3): 205-210. [38] Sun X, Li W, Zhang X, et al.2016. In vivo targeting and imaging of atherosclerosis using multifunctional virus-like particles of simian virus 40[J]. Nano Letters, 16(10): 6164-6171. [39] Swanson K A, Rainho-Tomko J N, Williams Z P, et al.2020. A Respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain[J]. Science Immunology, 5(47): eaba6466. [40] Tokatlian T, Read B J, Jones C A, et al.2019. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers[J]. Science, 363(6427): 649-654. [41] Wang W, Huang B, Zhu Y, et al.2021. Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice[J]. Cellular Molecular Immunology, 18(3): 749-751. [42] Wang L, Xing D, Le Van A, et al.2017. Structure-based design of ferritin nanoparticle immunogens displaying antigenic loops of Neisseria gonorrhoeae[J]. FEBS Open Bio, 7(8): 1196-1207. [43] Wang C Y, Chang T Y, Walfield A M, et al.2002. Effective synthetic peptide vaccine for foot-and-mouth disease in swine[J]. Vaccine, 20(19-20): 2603-2610. [44] Weidenbacher P A, Sanyal M, Friedland N, et al.2023. A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates[J]. Nature Communications, 14(1): 2149. [45] Wong H T, Cheng S C, Sin F W, et al.2002. A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2[J]. Vaccine, 20(21-22): 2641-2647. [46] Yan Y, Wang X, Lou P, et al.2020. A nanoparticle-based Hepatitis C virus vaccine with enhanced potency[J]. Journal of Infectious Diseases, 221(8): 1304-1314. [47] Yang F, Mariz F C, Zhao X, et al.2020. Broad neutralization responses against oncogenic human papilloma viruses induced by a minor capsid l2 polytope genetically incorporated into bacterial ferritin nanoparticles[J]. Frontiers in Immunology, 11: 606569. [48] Zhao L, Seth A, Wibowo N, et al.2014. Nanoparticle vaccines[J]. Vaccine, 32(3): 327-337. [49] Zhao Z, Chen X, Chen Y, et al.2021. A self-assembling ferritin nanoplatform for designing classical swine fever vaccine: Elicitation of potent neutralizing antibody[J]. Vaccines (Basel), 9(1): 45. [50] Zhen Z, Tang W, Zhang W, et al.2015. Folic acid conjugated ferritins as photosensitizer carriers for photodynamic therapy[J]. Nanoscale, 7(23): 10330-10333.
